Bionano Genomics (BNGO) Total Non-Current Liabilities (2017 - 2024)

Bionano Genomics has disclosed Total Non-Current Liabilities across 8 years of filings, most recently posting $41.3 million for Q4 2024.

• Total Non-Current Liabilities for Q4 2024 came in at $41.3 million, down 61.53% year-over-year; the trailing twelve-month figure through Dec 2024 was $41.3 million (down 61.53% YoY), and the FY2024 annual result was $41.3 million, down 61.53% from the prior year.
• Total Non-Current Liabilities came in at $41.3 million for Q4 2024 at Bionano Genomics, up from $38.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $107.4 million in Q4 2023 to a low of $17.9 million in Q3 2021.
• The 5-year median for Total Non-Current Liabilities is $41.3 million (2024), against an average of $41.3 million.
• Across the five-year window, Total Non-Current Liabilities surged 137.86% in 2023 and slumped 61.53% in 2024, its largest moves.
• Bionano Genomics' Total Non-Current Liabilities stood at $25.4 million in 2020, then gained by 21.87% to $30.9 million in 2021, then jumped by 45.99% to $45.1 million in 2022, then surged by 137.86% to $107.4 million in 2023, then plunged by 61.53% to $41.3 million in 2024.
• The last three Total Non-Current Liabilities figures came in at $41.3 million (Q4 2024), $38.5 million (Q3 2024), and $43.3 million (Q2 2024), per Business Quant data.